Navigation Links
Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders
Date:11/23/2009

CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ --

Dear Isis Supporters and Shareholders,

I would like to start by thanking you for your continuing support of Isis. We believe we are at one of the most successful moments in our history. We are truly at the end of the beginning of creating a unique company with a novel drug discovery platform, which we believe addresses many of the issues haunting the pharmaceutical industry.

Our progress is predicated largely upon the success of our flagship drug, mipomersen. Mipomersen continues to perform well and progress toward commercialization. Isis, our investigators and members of the medical community are very encouraged by the results that were presented at the AHA last week. To get a sense of their support of the drug, I would encourage you to listen to the replay of the mipomersen investigator panel presentation that was conducted during AHA last week. I think you will hear not only their enthusiasm for the drug but their hope that mipomersen will provide a new treatment alternative for their patients at very high risk of cardiovascular disease.

We are disappointed with the reaction on Wall Street to what we believe is very positive news. We believe mipomersen will continue to provide results that speak for themselves. Each success brings us closer to getting mipomersen to the market and making the drug available to patients in need.

Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve the productivity of the pharmaceutical industry. With 19 drugs in development, we have one of the largest and most diverse pipelines in our industry. We know that sick people depend on us. We continue to strive for excellence as we create drugs for the future. We also recognize that behind our successes is the support we receive from you. I would like to personally thank you for that.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
2. Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth Conference
3. Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
4. Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
5. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
6. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
7. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
8. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
9. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
10. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
11. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Philanthropic giving in the U.S. has ... and needs. Money for Good 2015, released today by Camber Collective, goes to the ... potential to mobilize up to $22B in new philanthropic giving and shift $25B that’s ...
(Date:9/1/2015)... ... September 01, 2015 , ... Consumers overwhelmingly ... Society for Dermatologic Surgery, according to a new survey that also offers insight ... Cosmetic Dermatologic Procedures – which reflects views on cosmetic medical treatments and ratings ...
(Date:9/1/2015)... ... September 01, 2015 , ... Virginia entrepreneur Marcella Ellis, CEO ... maintaining her firm’s success in the hair care and distribution industry through her ... Ellis will be providing “Look and learn” live demonstrations, as well as promoting ...
(Date:9/1/2015)... ... , ... The Jerry Segal Classic to benefit the patients of Magee Rehabilitation ... in Lafayette Hill, PA. Over the past 26 years, the Classic, organized by the ... designed to support patients and their families during their time at Magee Rehabilitation Hospital. ...
(Date:9/1/2015)... ... 01, 2015 , ... e-Spirit Inc., a leading supplier of ... Content Management System with new capabilities and enhancements designed to support the recently ... be well on their way to achieving digital transformation with less time and ...
Breaking Medicine News(10 mins):Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3
... can lay siege on the victim's disposition and way of ... of coolness can act as an effective pain// reliever. Scientists ... that enable feelings of coolness, and bring immense relief to ... for improved treatment measures for people suffering long-term pain, as ...
... President of the Canadian Medical Association (CMA) said that Canadian ... health of their own children// although in general they rated ... to a survey carried out by Ipsos-Reid, commissioned by the ... kids aged 2-17 are obese/overweight, however only 9% of Canadian ...
... are high during air travel, and not with other forms of ... blood clots can from during any form of travel where the ... has revealed that traveling for more than four hours by air, ... This was substantiated when the research team analyzed 2000 people, who ...
... phobia or fear of needles can be overcome by ... to researchers at the University of New Mexico's// (UNM) ... needles can impact the care a patient receives. ... of needles, whereas some adults avoid the doctor's office ...
... institutions claim to have found that nearly 19% of ... to a direct// result of war. ,Now ... would get the proper treatment necessary. Their fears see ... now mental health treatment from the Department of Veterans ...
... every month for several problems ranging from arthritis to ... enrolled// in Medicare Part D, the new federal prescription-drug ... plan paid for most of their drugs, minus $20 ... coverage stopped. Donna was told by a pharmacist that ...
Cached Medicine News:Health News:American War Veterans Not Receiving Enough Care For PTSD 2Health News:Many American senior citizens fall into the “Doughnut Hole” 2Health News:Many American senior citizens fall into the “Doughnut Hole” 3Health News:Many American senior citizens fall into the “Doughnut Hole” 4
(Date:9/1/2015)... California , September 1, 2015 ... is segmented on the basis of sectors, products ... chronic diseases globally coupled with the increasing demand ... diseases are expected to propel the growth for ... manage biological information efficiently is known as bioinformatics. ...
(Date:9/1/2015)... Aug. 31, 2015 Research and Markets ( ... "Regulatory Affairs for Support Staff (London, UK - September ... This two day course provides an introduction to ... and has been designed specifically for those working in ... gain an overview of EU regulatory procedures required to ...
(Date:9/1/2015)... 2015 - The ... egistry data presented at ESC Congress ... the evolution of manag ing AF in ... -   The first-ever two-year outcomes from the Global Anticoagulant ... expose that all-cause death was the most frequent major event in more than ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
... U.S. Food and Drug Administration today approved Ferriprox (deferiprone) ... transfusions in patients with thalassemia, a genetic blood disorder ... prior chelation therapy. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... iron in the body from the frequent blood transfusions ...
... SAN RAMON, Calif., Oct. 14, 2011 Armanino ... successful company-wide Microsoft Dynamics AX implementation and the ... MES (Manufacturing Engineering System) to streamline the production ... equipment.  Microsoft Dynamics AX is a comprehensive business ...
Cached Medicine Technology:FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body 2FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body 3Armanino Consulting Completes Integration of Microsoft Dynamics AX and Camstar MES for dpiX 2Armanino Consulting Completes Integration of Microsoft Dynamics AX and Camstar MES for dpiX 3
... the newest and most advanced automated immunoassay ... AIA-1800 launches with a full menu of ... reproductive, cardiac, and anemia assays. ,The AIA-1800 ... primary tube sampling, auto dilution, auto pretreatment, ...
EZ-PSA is a one-step immunoassay for the rapid, qualitative determination of human Prostate Specific Antigen (PSA) in whole blood. The test is intended for professional use as an aid in the diagnosis...
... name from its first known site of ... of PSA circulates bound to anti-chymotrypsin (PSA-ACT) ... PSA are elevated in patients with prostate ... [1-3]. In addition, PSA serum levels appear ...
... Functional Vision, Quality of Vision and ... both target illumination and glare luminance ... results. Day/Night testing with/without glare and ... and all ANSI standards. All Light ...
Medicine Products: